Parnell’s Noble Pharma acquisition expands U.S. veterinary drug manufacturing capacity. Read what it could change for supply, scale, and market strategy.
Endospan’s FDA-approved NEXUS system could reshape high-risk aortic arch repair. Read what the approval changes and what clinicians will watch next.
InterVene has completed 30 Recana cases, raising new questions about venous ISR treatment, adoption, and launch strategy. Read the full analysis.
Meiji Seika Pharma has launched Meiji Pharma Asia in Singapore. Read what this ASEAN expansion could change for vaccines and regional pharma growth.
Anixa Biosciences is advancing its breast cancer vaccine toward Phase 2 after positive Phase 1 data. Read what this means for oncology watchers.
Bambusa Therapeutics’ BBT001 showed strong Phase 1 activity in atopic dermatitis. Read what it could change and what risks remain.
Currax expands Contrave access through PeekDirect. Read what this could mean for obesity drug pricing, employers, and non-GLP-1 treatment adoption.
Imbed Biosciences secured CMS HCPCS code A2040 for Microlyte PainGuard. Read what it changes for wound care adoption, billing, and reimbursement.
ZEISS unveiled new AI, cataract planning, and cloud workflow tools at ASCRS 2026. Read what this means for ophthalmology practices.
Glaukos heads to ASCRS 2026 with Epioxa and glaucoma data. Read what this could change for keratoconus, sustained therapy, and adoption.